Research Publications

Back

Shutdown of immunological priming and presentation after in vivo administration of adenovirus


Sutherland, RM; Londrigan, SL; Brady, JL; Azher, H; Carrington, EM; Zhan, Y; Vega-Ramos, J; Villadangos, JA; Lew, AM
2012-11
GENE THERAPY
Journal Article
19
11
1095-1100
Adenoviral (Adv) vectors are widely used in both experimental and clinical trials for vaccination and gene therapy. Recombinant Adv can evoke potent innate immune responses and adaptive immune responses to encoded antigens. However, how Adv infection affects the response to subsequently encountered antigens is poorly understood. We show that intravenously administered replication defective (E1 and E3 deleted) Adv educes functional changes in dendritic cells (DC) resulting in impaired priming of cytotoxic T lymphocytes (CTL) more than 7 days after Adv treatment. Generalized DC activation was indicated by transient upregulation of CD86 and reduced endocytosis of fluorescent beads. It is known that CD8+ DC are predominantly responsible for uptake and presentation (cross-presentation) of exogenous antigens to CD8+ CTL. Hence, impaired endocytosis in CD8+, but not CD8+, DC at 7 days after Adv administration provided an explanation for the impaired CTL response to antigen at this time. Shutdown of cross-presentation was confirmed using cytochrome c (cytc), an agent that selectively depletes cross-presenting DC. Adv-infection rendered CD8+ DC resistant to depletion by cytc. As the cross-presentation pathway underlies CD8 T-cell responses to many cancers and to vaccines or viruses that do not directly infect DC, systemic Adv administration may impair these responses.
NATURE PUBLISHING GROUP
CD8(+) DENDRITIC CELLS; INNATE IMMUNE-RESPONSE; CROSS-PRESENTATION; GENE-TRANSFER; VECTORS; ACTIVATION; VACCINE; MATURATION; INFECTION; IMMUNIZATION
Immunology
10.1038/gt.2011.187
© 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.